Get notified when RNXT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Immediate Dilution of $0.78 Per Share (new) — New investors pay $1.07 per share while pro forma net tangible book value is only $0.29, resulting in immediate dilution of $0.78 per share.
- No Minimum Offering Amount (new) — The offering has no minimum size, so the company may receive little or no proceeds, creating uncertainty about funding for its clinical trial and commercialization plans.
RenovoRx launches at-the-market offering to sell up to $3.7M of common stock at $1.07/share
Filed November 14, 2025 · ~1 min read
Key Changes
-
high
RenovoRx may sell up to $3,723,029 of common stock in an at-the-market offering through JonesTrading, with shares priced at market.
The Offering verify on EDGAR → -
high
The offering is primary only; all proceeds go to the company, not selling stockholders.
The Offering verify on EDGAR → -
medium
Net proceeds are earmarked for working capital, the Phase III TIGeR-PaC study, and RenovoCath commercialization.
Use of Proceeds verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (IPW 10-K) is open in full — no account needed.
Partner
Trade RNXT commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify